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Abstract Uppergastrointestinalbleedingisthemostcommon
gastrointestinal emergency, with peptic ulcer as the most
common cause. Appropriate resuscitation followed by early
endoscopyfordiagnosisandtreatmentareofmajorimportance
in these patients. Endoscopy is recommended within 24 h of
presentation. Endoscopic therapy is indicated for patients with
high-risk stigmata, in particular those with active bleeding and
visible vessels. The role of endoscopic therapy for ulcers with
adherentclotsremainstobeelucidated.Ablativeormechanical
therapies are superiorto epinephrineinjection alonein terms of
prevention of rebleeding. The application of an ulcer-covering
hemospray is a new promising tool. High dose proton pump
inhibitors should be administered intravenously for 72 h after
endoscopyinhigh-riskpatients.Helicobacter pylori should be
tested for in all patients with peptic ulcer bleeding and
eradicated if positive. These recommendations have been
captured in a recent international guideline.
Keywords Peptic ulcer.Ulcer bleeding.Endoscopy.
Management.Pharmacotherapy.Review
Introduction
Upper gastrointestinal bleeding (UGIB) is the most common
gastrointestinal emergency, with peptic ulcer bleeding (PUB)
responsible for 31% to 67% of all cases, followed by erosive
disease (7% to 31%) and variceal bleeding (4% to 20%). Less
frequent causes are oesophagitis, Mallory Weiss tears and
neoplasm [1–6]. Peptic ulcer bleeding is associated with
considerable morbidity and mortality, which in various series
range between 5% and 13% [5]. The risk of mortality
strongly depends on age, the presence of comorbidity, the
severity of the bleed, and the occurrence of rebleeding [6].
Comorbidity as risk determinant explains why in-patients
with a bleeding episode have higher mortality rates than out-
patients presenting at the emergency unit. Endoscopy and
pharmacotherapy have become the mainstay in the manage-
ment of PUB. Endoscopy allows both identification of the
bleeding focus, classification of the risk of rebleeding, and
application of treatment in the same session, whereas
pharmacotherapy in particular aims at clot stabilization and
ulcer healing by profound acid suppression. This review
provides an update on the endoscopic management of peptic
ulcer bleeding.
Risk Assessment and Pre-Endoscopic Management
Pre-Endoscopic Resuscitation
Immediate evaluation and initiation of appropriate resuscita-
tionbymeansof administrationofIV fluids, oxygenand blood
transfusion when needed are of major importance in patients
presenting with UGIB. Red blood cell transfusions are,
depending on the underlying condition and clinical presenta-
tion generally administered once the hemoglobin level drops
below 70 g/L, but the impact of transfusion on rebleeding and
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of red blood cell transfusions in adults with UGIB were
assessed [7]. A total of three randomized or quasi-
randomized trials comparing red blood cell transfusion and
standard care without red blood cell transfusion included 126
patients. Red blood cell transfusion was, in these studies,
associated with more deaths (5% vs. 0%; 2 studies) and more
rebleeds (38% vs. 4%; 1 study). However, the included trials
were heterogeneous in treatment regimens and outcome
parameters and had several methodological deficiencies,
which implied that the results of the meta-analysis can only
be used as a stimulus for further studies, but not for firm
clinical guidelines. In a large recent UK study, data on 4441
patients with acute UGIB were collected. Patients who
received transfusion within 12 h of presentation had a
twofold increased rate of rebleeding (OR 2.26; 95% CI
1.76–2.90) and a 28% increase in mortality (OR 1.28; 95%
CI 0.94–1.74) compared to those not early transfused. These
results persisted after correction for the severity of the bleed
using Rockall scores and haemoglobin concentrations at
presentation, the results may have been biased by persistent
differences in case mix between early transfused and non-
transfused patients [8]. Prospective studies with a strict
defined transfusion protocol are needed. In the meantime,
the risks and benefits of red blood cell transfusion must be
carefully weighted individually.
Pharmacotherapy Prior to Endoscopy
Intravenous administration of high dose proton pump
inhibitors (PPIs) prior to endoscopy neutralizes pH and
leads to stabilization of blood clots. Investigators from
Hong Kong studied the effect of preemptive infusion of
omeprazole administered as an 80-mg intravenous bolus
followed by an 8-mg infusion per hour before endoscopy in
638 patients with UGIB. They found a significant reduction
in the need for endoscopic therapy (19% vs. 28%, P=
0.007) with fewer active bleeds during endoscopy (6% vs.
15%, P=0.01) and more ulcers with clean base (64% vs.
47%, P=0.001) in the omeprazole-treated patients [9]. No
effect was found on other major outcome parameters as the
need for transfusion, rebleeding and mortality. Therefore,
international guidelines remark that pre-endoscopic PPI
therapy may be considered to downstage the bleeding site
and decrease the need for endoscopic intervention, but that
this should not delay endoscopy [10￿￿].
Risk Assessment
Early risk assessment is crucial to determine the optimal
timing of endoscopy, to define patients at highest risk of
rebleeding, and to predict the need for other measures as
administration of IV fluids, blood transfusion, and intensive
care admission. For this purpose, several risk classification
systems have been developed. Two frequently used scoring
systems are the Blatchford score and the Rockall score [11,
12]. The latter contains a pre-endoscopic part, as well as a
post-endoscopic component including the results of endos-
copy. Both the Blatchford and Rockall scoring systems
consider vital signs at presentation and comorbidity. The
Blatchford score is more focused on symptoms (melena
and/or syncope) and laboratory results (hemoglobin and
urea) compared to the Rockall score, but does not consider
age. A recent prospective cohort study comparing the
validity and usefulness of these scoring systems concluded
that the Blatchford score, but not the pre-endoscopic
Rockall score, is useful for predicting low-risk patients
who do not need therapeutic endoscopy and who may be
suitable for outpatient management [13]. Disappointingly,
the positive predictive value of both scores for the need for
endoscopic intervention was low. This supports initiatives
to adapt existing scorings systems or develop new, aiming
for more precise risk stratification.
Time to Endoscopy
International consensus guidelines recommend early endosco-
py within 24 h of presentation for patients with acute upper
gastrointestinal bleeding [10￿￿]. Data from a nationwide UK
survey of 6750 patients seen in 208 hospitals with UGIB
show that this recommendation is not widely followed. Of
patients deemed at high risk, only 55% received endoscopy
within 24 h [4￿]. A main reason for delayed endoscopy was
the absence in half of the hospitals of a formal out of hours
endoscopy rota or service with a consultant available on call.
Early endoscopy is safe and effective for all risk groups,
allows timely diagnosis and treatment, reduces use of
resources and length of hospital stay, and decreases the
need for surgery [10￿￿]. So far, no additional benefit from
very early or urgent (<12 h) endoscopy was found
compared with early endoscopy (<24 h) with respect to
rebleeding, surgery or mortality [14, 15]. However, emergen-
cy endoscopy should be performed as soon as possible after
hemodynamic stabilization in selective patients who are
hemodynamically unstable or have massive hematemeses.
Endoscopic Therapy
Endoscopic Features and the Need for Therapy
The endoscopic appearance of peptic ulcers provides impor-
tant prognostic information and can identify ulcers as those
with high versus low risk of rebleeding. Ulcers with signs of
active spurting (Fig. 1) or oozing hemorrhage (resp. Forrest
Ia and Ib) and ulcers with a visible vessel (Forrest IIa) are at
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contrast, ulcers with a clean base or flat spot in the ulcer bed
(resp. Forrest III and IIc) do only rebleed in 4% to 13% of
cases [16]. Ulcers with adherent clots have an intermediate
risk of rebleeding (about 25%), depending on the underlying
lesion. For that reason, clot removal should be attempted by
vigorous irrigation.
Endoscopic haemostatic therapy is indicated for patients
with high risk ulcers, while patients with low-risk stigmata can
be treated with pharmacotherapy alone. The optimal manage-
ment of bleeding peptic ulcers with adherent clot remains
controversial. Two meta-analyses have addressed this issue.
The first included six studies involving 240 patients from the
United States, Southeast Asia, and Europe and found a
significantly lower risk of rebleeding in the patients who
underwent endoscopic therapy compared with the medical
therapy group (8 vs. 25%, P=0.01). The interventions yielded
similar results with respect to the need for surgery, transfusion
requirement, length of hospital stay and mortality [17]. The
validity of this meta-analysis was however questioned since
studies with heterogeneous designs were combined and most
studies used suboptimal PPI dosage in the control group [18].
A more recent meta-analysis, including five trials, comprising
189 patients, found no significant benefit of endoscopic
therapy in patients with ulcers with adherent clots [19￿]. So
far, endoscopic therapy should be considered, although
intensive PPI therapy may be sufficient among patients with
adherent clots resistant to vigorous irrigation.
Injection Therapy
Injection therapy with epinephrine is widely used for the
treatment of PUB because it is inexpensive, easy to
administer, and effective. Acute hemostasis is achieved by
local tamponade, vasospasm, and induction of thrombosis.
These effects resolve after about 20 min and it is therefore
recommended to combine injection therapy with a more
durable endoscopic technique [10￿￿].
O t h e rs u b s t a n c e su s e di na d d i t i o nt oo ra sa na l t e r n a t i v et o
epinephrine are sclerosants (eg polidocanol, ethanolamine,
and ethanol), fibrin sealant, and on some occasions n-butyl
cyanoacrylate. However, the use of sclerosants for the
treatment of PUB is nowadays limited, because they can
cause serious local side-effects and in addition to epinephrine
confer minimal additional benefit [20]. Fibrin sealant or glue
is a relatively new agent for the treatment of PUB. It was
shown to be more effective in preventing rebleeding than
injection with polidocanol, but only if repeatedly injected
[21]. Also, for that reason, it is not generally used in clinical
practice. N-butyl cyanoacrylate is in particular used for
gastric variceal bleeds, but is on rare occasions also applied
to bleeding peptic ulcers with massive bleeds as a last resort,
with the risk of arterial embolization [22].
Ablative and Mechanical Therapies
Several meta-analyses compared the effects of mechanical
therapies (eg hemoclip placement), ablative therapy (eg heater
probe and Gold probe), and injection therapy (eg epinephrine,
fibrin glue and sclerosants) for hemostasis and prevention of
rebleeding in peptic ulcer bleeding [19￿, 23–26]( T a b l e1). This
yielded two important messages. The first is that although
epinephrine injection is more effective than acid suppressive
therapy alone in patients with high risk stigmata, epinephrine
monotherapy is inferior to other monotherapies as well as to
combination therapy [19￿, 23–25]. This means that epine-
phrine should no longer be applied as monotherapy, but only
in combination with other methods. The second major
message from the meta-analyses was that none of the ablative
or mechanical therapies were superior over the others.
Dual therapy (ie epinephrine injection plus other
injection or thermal or mechanical method) proved signif-
icantly superior to epinephrine injection alone, but had no
advantage over thermal or mechanical monotherapy [23].
In specific situations, eg difficult-to-approach or indi-
rectly visualized bleeding sites, heater probe therapy can be
superior to hemoclip placement [27].
Hemospray
A potentially very important new development is the intro-
duction of a hemospray which can be directly applied via a
catheter through the working channel. This nanopowder with
clotting abilities has been shown to be highly effective for
achieving hemostasis of arterial bleeding in a heparinized
animal model. When sprayed on a bleeding site, the powder
becomescohesiveandadhesive,andformsastablemechanical
Fig. 1 Forrest Ia ulcer bleeding in a small gastric ulcer
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pilot study on 20 adults with confirmed PUB (Forrest 1a
or 1b), acute hemostasis was achieved in 95%. Rebleeding
occurred in two patients (shown by hemoglobin drop), but no
active bleeding was seen during repeat endoscopy in these
patients. No mortality or adverse events were reported during
30-dayfollow-up[28￿]. Further studies on the effectiveness of
hemospray, also for other causes of UGIB, are ongoing.
Second Look Endoscopy
Few data support the overall benefit of a routine repeat
endoscopy after endoscopic hemostasis. Those studies
which did report a benefit from routine second look were
in part of older date and did not include the use of PPIs or
modern endoscopic haemostatic techniques. Therefore,
second look endoscopy is not routinely recommended,
however it may be beneficial in selected patients at high
risk of rebleeding [10￿￿, 29, 30].
Post-Endoscopic Management
Surgery or Angiographic Embolization
Although endoscopic therapy is highly effective, sometimes
bleeding cannot be stopped or recurs. In case of recurrent
bleedingasecondattemptatendoscopictreatmentisgenerally
recommended [10￿￿]. With persistent or renewed bleeding,
emergency surgery and selective transcatheter arterial embo-
lization (TAE) of the bleeding artery are rescue modalities.
In a retrospective analysis of 70 cases with refractory
PUB, no differences were found between patients treated
with TAE versus surgery in the incidence of recurrent
bleeding (29% vs. 23.1%), need for additional intervention
(16.1% vs. 30.8%), or death (25.8% vs. 20.5). The lack of
difference and the fact that the patients in the TAE group
were older (75 year vs. 63 year, P<0.001) and had more
comorbidity, suggests a slight advantage of TAE [31]. There
is a pressing need for randomized controlled trials to
prospectively compare these two techniques.
Acid Suppressive Therapy
High dose intravenously administered PPI therapy (80 mg
bolus, followed by 8 mg/h continuous infusion for 72 h) is
recommendedtoreducerebleedinginPUBpatientswithhigh-
risk stigmata at endoscopy. This guideline recommendation is
supported by a meta-analysis in which high dose IV PPI
therapy significantly improved outcome compared with
placebo/no therapy (RR, 0.40 [95% CI, 0.28-0.59]; NNT, 12
[95% CI, 10-18]) [19￿]. In Asian patients, this beneficial
effect has been achieved with different PPIs [32]. In
Caucasian patients, who on average, have higher acid output,
a significant effect on major outcome parameters such as
rebleeding has only been achieved with high-dose continu-
ous esomeprazole infusion [33]. Patients at low risk can be
fed within 24 h and early discharged with oral PPI therapy.
Further Measures
In all patients, oral treatment with a PPI is generally
recommended for 4 weeks, as this is sufficient to heal nearly
all ulcers and address the underlying cause of the bleeding
ulcer. Helicobacter pylori infection and the use of non-
steroidal anti-inflammatory drugs (NSAIDs) are the main
risk factors for the development of peptic ulcer disease.
Therefore, every patient with a PUB should be tested for H.
pylori and receive eradication therapy if applicable. Invasive
tests obtained in the acute setting may yield false-negative
Table 1 Recent meta-analyses comparing endoscopic techniques for treatment of peptic ulcer bleeding





Marmo 2007 [23] 20 2472 Epinephrine injection +other injection or
thermal or mechanical method vs.
monotherapy with one of these methods
Dual endoscopic therapy is superior to
epinephrine injection alone, but not to thermal
or mechanical monotherapy
Sung 2007 [24] 15 1156 Hemoclips vs. injection/thermocoagulation Hemoclip placement is superior to injection
alone but comparable to thermocoagulation
Yuan 2008 [26] 12 699 Hemoclips vs. other endoscopic techniques Hemoclip placement is not superior to other
endoscopic modalities
Laine 2009 [19] 65 6237 Thermal devices, sclerosant, hemoclips,
fibrin glue and epinephrine
Thermal devices, sclerosant, clips and fibrin glue
are comparable. Epinephrine monotherapy is
inferior to other interventions.
Barkun 2009 [25] 41 4261 Pharmacotherapy, injection,
thermocoagulation, clips or combinations
All endoscopic therapies are superior to
pharmacotherapy alone. Thermal therapy or
clips alone or in combination with injection
are comparable
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evidence of H. pylori infection [10￿￿]. A total of 1 month
after antimicrobial therapy, patients should be reassessed for
successful eradication, as persistent H. pylori infection is
associated with a more than 50% risk of recurrent ulcer
disease within 2 years, and thus, with a significant risk for
recurrent ulcer complications including bleeding [34].
Patients who developPUB while on NSAIDtherapy,should
be considered for permanent withdrawal of such therapy. If this
is not feasible, they should preferentially switch to the
combination of a selective COX2-inhibitor together with PPI
gastroprotection since a COX2-inhibitor alone, as well as a
conventional NSAID with a PPI are both associated with a
persistent rebleeding risk [10￿￿, 35]. The need for adequate
adherence to the gastroprotective PPIs should be stressed, as
various studies have now shown that even moderate lack of
adherence significantly increases the risk of events [36, 37].
In patients who develop ulcer bleeding while on low
dose aspirin, the need for this therapy should also be
reassessed. In many, low dose aspirin is given for secondary
prevention of cardiovascular disease. In these patients,
continuation of antiplatelet treatment during the bleeding
episode may increase rebleeding but reduces all-cause
mortality rates. This was concluded by a recent RCT
including 156 low-dose aspirin users for secondary cardio-
vascular prophylaxis. After endoscopic treatment for peptic
ulcer bleeding, these patients were randomly assigned to
either continue aspirin or receive placebo, both in combi-
nation with 72 h high dose IV PPI followed by an oral PPI
for 8 weeks. The 30-day rebleeding rate was not signifi-
cantly higher in the aspirin than in the placebo group (10.3
vs. 5.4%; Δ 4.9% [95% CI −3.6–13.4]), but the all-cause
mortality (1.3% vs. 12.9%; Δ 11.6% [CI, 3.7–19.5%]) and
the mortality rates attributable to cardiovascular, cerebro-
vascular or gastrointestinal complications (1.3% vs. 10.3%
Δ 9% [CI, 1.7–16.3%]) were significantly lower in the
aspirin group [38￿]. Until now, no prospective studies have
been performed to study shorter intervals of discontinuation
of aspirin. The optimal period of discontinuation is thus not
yet defined. For now, guidelines recommend to restart
aspirin 3 to 5 days after endoscopic therapy, provided that
the patients hemodynamic condition is stable [29].
Patients with idiopathic ulcer disease, ie those in whom
adequate assessment does not reveal an underlying cause,
should also be treated with PPI maintenance therapy as they are
at considerable risk for recurrent ulcer formation and bleeding
[39].
Future Research
In the past 2 decades, major developments took place in the
management of peptic ulcer bleeding. Proton pump inhib-
itors were introduced, H. pylori was recognized as an
important risk factor for the development of peptic ulcers,
and endoscopic therapy had become the main therapy for
the majority of patients with peptic ulcer bleeding. Despite
these valuable new discoveries, PUB incidence remained
stable and probably will even rise in the near future due to
aging of the population accompanied by increasing use of
medication and comorbid illness.
Therefore, there is a pressing need for studies to elucidate
the optimal time to endoscopy, the optimal approach to
patients with adherent clots, the most effective endoscopic
techniques and the best alternative for patients refractory to
endoscopic therapy. In addition, development of an appropri-
ate risk stratification scorings system and safe transfusion
policy will be important topics for future research.
Conclusions
Peptic ulcer bleeding is the most frequent emergency
condition in gastroenterology practice. It is associated with
significant morbidity and mortality. Endoscopy is the main-
stay in the modern management of PUB. Ideally endoscopy
shouldbeperformedwithin24hofpresentation.Combination
therapy of epinephrine injection plus another hemostatic
technique or the use of another hemostatic technique alone
is more effective than epinephrine alone. Hemospray is a new
promising endoscopic therapy. Patients with high-risk stigma-
ta should receive continuous IV PPI administration for 72 h
afterendoscopy.Aftertheacutephase,theunderlyingcauseof
the ulcer should be verified and treated when possible.
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